Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery

References

• Aleem O, Kucheka B, Pore Y, Late S. (2008). Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J Pharm Biomed Anal. 47, 535–540.
   PubMed Web of Science ®Google Scholar
• Andersson MI, MacGowan AP. (2003). Development of the quinolones. J Antimicrob Chemother. 5, 1–11.
   Google Scholar
• Arredondo GJL, Figueroa DR, Rosas A. (2004). Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother. 54, 840–843.
   PubMed Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar MN. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carr Syst. 21, 387–422.
   PubMed Web of Science ®Google Scholar
• Beaulac C, Clément-Major S, Hawari J, Lagacé J. (1996). Eradication of mucoid Pseudomonas aeruginosa with £uid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemo-ther. 40, 665–669.
   PubMed Web of Science ®Google Scholar
• Beaulac C, Sachetelli S, Laglce J. (1998). In-vitro bactericidal efficacy of sub-MIC concentration of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria. J Antimicrob Chemother. 41, 35–41.
   PubMed Web of Science ®Google Scholar
• Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R, Kumar MNV. (2005). Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotechnol. 1, 235–258.
   Web of Science ®Google Scholar
• Boerema JB, Saene HKV. (1986). Norfloxacin treatment in complicated urinary tract infection, Scand. J Infect Dis. Suppl. 48, 20–26.
   Google Scholar
• Breda SA, Jimenez-Kairuz AF, Manzo RH, Olivera ME. (2009). Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives. Int J Pharm. 371, 106–113.
   PubMed Web of Science ®Google Scholar
• Brown SA. (1996). Fluoroquinolones in animal health. J Vet Pharmacol Therap. 19, 1–14.
   PubMed Web of Science ®Google Scholar
• Carratalá J, Fernández-Sevilla A, Tubau FE, Callis M, Gudiol F. (1995). Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 20, 557–560.
   PubMed Web of Science ®Google Scholar
• Carratala J, Roson B, Fernandez-Sevilla A, Alcaide F, Gudiol F. (1998). Bacteremic pneumonia in neutropenic patients with cancer causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 158, 868–872.
   PubMed Web of Science ®Google Scholar
• Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery–some emerging concepts. J Pharm Sci. 89, 967–978.
   PubMed Web of Science ®Google Scholar
• Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 233, 51–59.
   PubMed Web of Science ®Google Scholar
• Desai MP, Labhasetwar V, Amidon GL, Levy RJ. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 13, 1838–1845.
   PubMed Web of Science ®Google Scholar
• Eandi M, Viano I, Nola FD, Leone L, Genazzani E (1983). Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. Eur. J. Clin. Microbiol. 2, 253–259.
   PubMedGoogle Scholar
• Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinarvaand R. (2007). Preparation and antibacterial activity evaluation of rifampicin-loaded poly-lactide-co-glycolide nanoparticles. Nanomedicine Nanotechnology, Biology and Medicine. 3, 161–167.
   PubMed Web of Science ®Google Scholar
• Fernández J, Arbol LR, Gómez C. (2006). Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 131, 1049–1056.
   PubMed Web of Science ®Google Scholar
• Ferrero L, Cameron B, Crouzet J. (1995). Analysis of gyrA and gyrB mutations in stepwise-selected ciprofloxacin-resistant mutants of staphylococcus aureus. Antimicrob Agents Chemother. 39, 1554–1558.
   PubMed Web of Science ®Google Scholar
• Gao F, Yang P, Xie J, Wang HF. (1995). Synthesis, characterization and antibacterial activity of novel Fe(III), Co(II), and Zn(II) complexes with norfloxacin. J Inorg Biochem. 60, 61–67.
   PubMed Web of Science ®Google Scholar
• Garcia-Fuentes M, Torres D, Alonso MJ. (2002). Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B: Biointerfaces. 27, 159–168.
   Web of Science ®Google Scholar
• Gips M, Soback, S. (1996). Norfloxacin nicotinate pharmacokinetics in unwearied and weaned calves. J Vet Pharmacol Ther. 19, 130–134.
   PubMed Web of Science ®Google Scholar
• Guyot M, Fawaz F, Bildet J, Bonini FAM, Lagueny. (1995). Physicochemical characterization and dissolution of norfloxacin cyclodextrin inclusion compounds and PEG solid dispersions. Int J Pharm. 123, 53–63.
   Web of Science ®Google Scholar
• Han C, Qi CM, Zhao BK, Cao J, Xie SY, Wang S, Zhou WZ. (2009). Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Vet Pharmacol Ther. 32, 116–123.
   PubMed Web of Science ®Google Scholar
• Han YX, Wu X, Yang JH, Sun SN. (2005). The fluorescence characteristic of the yttrium–norfloxacin system and its analytical application. J Pharm Biomed Anal, 38, 528–531.
   PubMed Web of Science ®Google Scholar
• Hans H, Li SG. (1991). Norfloxacin, next term the first of a new class of fluoroquinolone antimicrobials, revisited. Int J Antimicrob Agents. 1, 3–28.
   PubMedGoogle Scholar
• Hooper DC, Wolfson JS. (1985). The Fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 28, 716–721.
   PubMed Web of Science ®Google Scholar
• Hou LL, Zhao XB, Ma YK, Zhai GX, Li LB, Lou HX. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Controlled Release. 133, 238–244.
   PubMed Web of Science ®Google Scholar
• Hu FQ, Yuan H, Zhang HH, Fang M. (2002). Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization–selected. Int J Pharm. 239, 121–128.
   PubMed Web of Science ®Google Scholar
• Hussain N, Jaitley V, Alexander TF. (2001). Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev. 50, 107–142.
   PubMed Web of Science ®Google Scholar
• Jani PU, McCarthy DE, Florence AT. (1992). Nanosphere and microsphere uptake via Peyer’’s patches: observation of the rate of uptake in rat after a single oral dose. Int J Pharm. 86, 239–246.
   Web of Science ®Google Scholar
• Jenninga V, Schäfer-Kortingb M, Gohla S. (2000). Vitamin A–loaded solid lipid nanoparticles for topical use: drug release properties. J Controlled Release. 66, 115–126.
   PubMed Web of Science ®Google Scholar
• Kalaria DR, Sharma G, Beniwal V, Kumar MNVR. (2008). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 26, 492–501.
   PubMed Web of Science ®Google Scholar
• Lavy E, Ziv G, Glickman A. (1995). Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. J Vet Pharmacol Ther. 18, 101–107.
   PubMed Web of Science ®Google Scholar
• Levy MY, Schutze W, Fuhrer C, Benita S. (1994). Characterization of diazepam submicron emulsion interface: role of oleic acid. J Microencapsul. 11, 79–92.
   PubMed Web of Science ®Google Scholar
• Li HL, Zhao XB, Ma YK, Zhai GX, Li LB, Lou HX. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Controlled Release. 133, 238–244.
   PubMed Web of Science ®Google Scholar
• Li XF, Carter SJ, Dovichi NJ. (2000). Non-aqueous capillary electrophoresis of tamoxifen and its acid hydrolysis products. J Chromatogra A. 895, 81–85.
   PubMed Web of Science ®Google Scholar
• Luo YF, Chen DW, Ren LX, Zhao XL, Qin J. (2006). Solid lipid nanoparticles for enhancing vinpocetine’’s oral bioavailability. J Controlled Release. 114, 53–59.
   PubMed Web of Science ®Google Scholar
• Kaplowitz L, Vishniavsky N, Evans T. (1987). Norfloxacin in the treatment of uncomplicated gonococcal infections. Am J Med, 82, 35–39.
   PubMed Web of Science ®Google Scholar
• Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 41, 189–207.
   PubMedGoogle Scholar
• Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Controlled Release. 107, 215–228.
   PubMed Web of Science ®Google Scholar
• Misra R, Acharya S, Dilnawaz F, Sahoo SK. (2009). Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-co-glycolide) and poly(ϵ-caprolactone) nanoparticles. Nanomedicine. 4, 519–530.
   PubMed Web of Science ®Google Scholar
• Mühlen AZ, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery–Drug release and release mechanism. Eur J Pharm Biopharm. 45, 149–155.
   PubMed Web of Science ®Google Scholar
• Müller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 113, 151–170.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. Eur J Pharm Biopharm. 50, 161–177.
   PubMed Web of Science ®Google Scholar
• Munoz A, Guichard JP, Reginault P. (1994). Micronised fenofibrate. Atherosclerosis. 110, 45–48.
   PubMed Web of Science ®Google Scholar
• Nordskog BK, Phan CT, Nutting DF. (2001). An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev. 50, 21–44.
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 85, 227–234.
   PubMed Web of Science ®Google Scholar
• Pandey R, Sharma S, Khuller GK (2005). Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis. 85,415–420.
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev. 55, 329–347.
   PubMed Web of Science ®Google Scholar
• Pittman W, Moon JO, Hamrick LC, Cox CE, Clark J, Childs S, Pizzuti D, Fredericks J, Clair PS. (1993). Randomized double-blind trial of high-and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection. Am J Med. 94, 101–104.
   Web of Science ®Google Scholar
• Porter CJH, Charman WN. (2001). In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 50, 127–147.
   PubMed Web of Science ®Google Scholar
• Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. (1987). Oral use of ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim sulfamethoxazole-resistant bacteria. Amer J Med. 82, 295–297.
   PubMed Web of Science ®Google Scholar
• Sachetelli S, Khalil H, Chen T, Beaulac C, Sénéchal S, Lagacé J. (2000). Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta. 1463, 254–266.
   PubMed Web of Science ®Google Scholar
• Smith CR. (1987). The adverse effects of fluoroquinolones, J Antimicrob Chemoth. 19, 709–712
   PubMed Web of Science ®Google Scholar
• Üner M. (2006). Preparation, characterization and physico-chemical properties of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Their benefits as colloidal drug carrier systems.Pharmazie. 61, 375–386.
   PubMed Web of Science ®Google Scholar
• Vasir JK, Tambwekar K, Garg S. (2003). Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 255, 13–32.
   PubMed Web of Science ®Google Scholar
• Verhoef J, Rozenberg-Arska M. (1989). Prevention of bacterial and fungal infections in granulocytopenic patients. Eur J Cancer. 25, 1345–1350.
   Web of Science ®Google Scholar
• Wella M, Nabera KG, Kinzig-Schippersb M, Sörgelb F (1998). Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Ag. 10, 31–38.
   PubMed Web of Science ®Google Scholar
• Wolfson JS, Hooper DC. (1988). Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med. 108, 238–251.
   PubMed Web of Science ®Google Scholar
• Xie SY, Pan BL, Wang M, Zhu LY, Wang FH, Dong Z, Wang XF, Zhou WZ.(2010). Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil-solid lipid nanoparticles, Nanomedicine.5, 693–701
   PubMed Web of Science ®Google Scholar
• Xie SY, Wang SL, Zhao BK, Han C, Wang M, Zhou WZ. (2008). Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B: Biointerfaces. 67, 199–204.
   PubMed Web of Science ®Google Scholar
• Xie SY, Wang SL, Zhu LY, Wang FH, Zhou WZ. (2009). The effect of glycolic acid monomer ratio on the emulsifying activity of PLGA in preparation of protein-loaded SLN. Colloids Surf B: Biointerfaces. 74, 358–361
   PubMed Web of Science ®Google Scholar
• Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. (2007). Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B: Biointerface. 58,157–164.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. (2008). Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther. 83, 761–769.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Yie GQ, Li Y, Yang Q, Nagai T. (2000). Studies on the cyclosporin a loaded stearic acid nanoparticles. Int J Pharm. 200, 153–159.
   PubMed Web of Science ®Google Scholar